Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data.

ABSTRACT: Recently, guidelines for endometrial cancer (EC) were released that guide treatment decisions according to the tumors' molecular profiles. To date, no real-world data regarding the clinical feasibility of molecular profiling have been released. This retrospective, monocentric study investigated the clinical feasibility of molecular profiling and its potential impact on treatment decisions. Tumor specimens underwent molecular profiling (testing for genetic alterations, (immune-)histological examination of lymphovascular space invasion (LVSI), and L1CAM) as part of the clinical routine and were classified according to the European Society for Medical Oncology (ESMO) classification system and to an integrated molecular risk stratification. Shifts between risk groups and potential treatment al

SUBMITTER: Oberndorfer F 

PROVIDER: S-EPMC7830511 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature